Enlivex Therapeutics Stock Z Score
| ENLV Stock | USD 1.14 0.07 6.54% |
Enlivex | Z Score |
Enlivex Therapeutics Company Z Score Analysis
Enlivex Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Enlivex Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Enlivex Therapeutics is extremely important. It helps to project a fair market value of Enlivex Stock properly, considering its historical fundamentals such as Z Score. Since Enlivex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Enlivex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Enlivex Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
According to the company's disclosures, Enlivex Therapeutics has a Z Score of 0.0. This is 100.0% lower than that of the Software sector and 100.0% lower than that of the Information Technology industry. The z score for all United States stocks is 100.0% higher than that of the company.
Enlivex Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enlivex Therapeutics' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enlivex Therapeutics could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics of similar companies.Enlivex Therapeutics is currently under evaluation in z score category among its peers.
Enlivex Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Enlivex Therapeutics from analyzing Enlivex Therapeutics' financial statements. These drivers represent accounts that assess Enlivex Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Enlivex Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 72.6M | 111.0M | 111.6M | 72.5M | 50.2M | 50.2M | |
| Enterprise Value | 68.7M | 105.5M | 101.0M | 29.5M | 50.4M | 41.9M |
Enlivex Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Enlivex Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Enlivex Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Enlivex Therapeutics' value.| Shares | Steward Partners Investment Advisory, Llc | 2024-06-30 | 3 K | Jpmorgan Chase & Co | 2024-09-30 | 1.8 K | Activest Wealth Management | 2024-09-30 | 1000 | Srs Capital Advisors Inc | 2024-09-30 | 615 | Advisor Group Holdings, Inc. | 2024-06-30 | 400 | Global Retirement Partners, Llc. | 2024-09-30 | 11.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | Barclays Plc | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 2.1 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 245.8 K |
Enlivex Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 1.33 M | ||||
| Shares Outstanding | 21.41 M | ||||
| Shares Owned By Insiders | 5.73 % | ||||
| Shares Owned By Institutions | 18.80 % | ||||
| Number Of Shares Shorted | 99.23 K | ||||
| Price To Earning | (11.97) X | ||||
| Price To Book | 0.85 X | ||||
| EBITDA | (28.22 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 62.48 M | ||||
| Cash Per Share | 3.40 X | ||||
| Total Debt | 1.03 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 15.44 X | ||||
| Book Value Per Share | 1.62 X | ||||
| Cash Flow From Operations | (23.52 M) | ||||
| Short Ratio | 0.56 X | ||||
| Earnings Per Share | (0.98) X | ||||
| Target Price | 9.5 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 24.4 M | ||||
| Total Asset | 36.83 M | ||||
| Retained Earnings | (112.09 M) | ||||
| Working Capital | 27.7 M | ||||
| Current Asset | 6 M | ||||
| Current Liabilities | 671.32 K | ||||
| Net Asset | 36.83 M |
About Enlivex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enlivex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enlivex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enlivex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.